Sientra Reports Seventh Consecutive Quarter of Record Growth for First Quarter 2022

Record Growth Driven by Continued Expansion of Augmentation and Reconstruction Accounts

Accelerated Gross Margin Improvement Through Execution of Commercial and Operational Plans

SANTA BARBARA, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced its financial results for the first quarter that ended March 31, 2022.

Q1 2022 Financial and Business Highlights

• Net sales of $21.4 million, representing growth of 17% over the first quarter of 2021, driven by 50% year-over-year growth in reconstruction.
• Gross margins of 60%, reflecting strong reconstruction performance and improved operational efficiencies.
• Expanded market share in both reconstruction and augmentation segments, adding over 200 new accounts.
• Hosted first ever R&D Day highlighting Sientra’s strategic vision and innovation pipeline.
• Commenced clinical study for novel fat grafting technology, with commercial plans on track for launch in early 2023.
• Grew Sientra’s brand awareness, becoming the second most recognized breast implant brand among consumers.¹
• Augmentation market share hit an all-time high of approximately 13% at the end of the first quarter.²
  

Ron Menezes, Sientra’s President and Chief Executive Officer, said, “We are off to a strong start in 2022 as our team continues to execute well on our key growth strategies. We are very excited about the reemergence of reconstruction for accelerated expansion in the plastic surgery market, and sustainable, long-term growth driven by both reconstruction and augmentation.”

“A key goal is to become a leader in reconstruction and the way we started 2022 positions Sientra closer to that goal. We believe our history of best-in-class innovation, safety and clinically-proven 10-year data will allow us to further penetrate our end markets, particularly reconstructive surgery, where we are seeing some of the strongest growth trends,” concluded Menezes.

______________________________
¹ Sientra Brand and Awareness Tracking Study, February 2022 (data on file)
² Ronan Solutions: Primary + Secondary Augmentation Data compared to Sientra procedural units shipped (data on file)

First Quarter 2022 Financial Results

• Total net sales were $21.4 million, an increase of 17% compared to total net sales of $18.3 million for the same period in 2021.
  
  
• Gross profit for the first quarter 2022 was $12.8 million, or 60.0% of sales, compared to gross profit of $10.2 million, or 55.4% of sales, for the same period in 2021.
  
  
• Operating expenses for the first quarter 2022 of $28.9 million compared to $21.9 million for the same period in 2021.
  
  
• Loss from continuing operations for the first quarter 2022 was $18.0 million, or $(0.29) per share, compared to $56.6 million, or $(1.04) per share, for the same period in 2021.
  
  
• On a non-GAAP basis, adjusted EBITDA loss for the first quarter 2022 was $11.8 million as compared to an adjusted EBITDA loss of $7.3 million for the same period in 2021.
  
  
• Net cash and cash equivalents as of March 31, 2022, were $38.9 million, compared to $51.8 million at December 31, 2021.
  

Full Year 2022 Guidance

For full year 2022, the Company expects to achieve total net sales of $93 million to $97 million, representing growth of 15% to 20% compared to net sales of $80.7 million in 2021. GAAP operating expense is expected to be $105 million to $109 million representing an increase of 16% to 20% compared to GAAP operating expense of $90.7 million in 2021. Non-GAAP operating expense is expected to be $90 million to $94 million representing an increase of 18% to 23% compared to Non-GAAP operating expense of $76.3 million in 2021.

Conference Call

Sientra will hold a conference call today, May 12, 2022, at 4:30 pm ET to discuss first quarter 2022 results. The dial-in numbers are 1-877-270-2148 for domestic callers and 1-412-902-6510 for international callers. The conference ID is 10166923. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.  

Use of Non-GAAP Financial Measures

Sientra has supplemented its US GAAP net income (loss) with a non-GAAP measure of Adjusted EBITDA and US GAAP Operating Expenses with a non-GAAP measure of Non-GAAP Operating Expenses. Management believes that these non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the Company, facilitate a more meaningful comparison of results for current periods with previous operating results, and assist management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. Reconciliations of non-GAAP Adjusted EBITDA and Non-GAAP Operating Expenses to GAAP net income (loss) and GAAP Operating Expenses, the most directly comparable GAAP measures, are provided in the schedules below. In the current period, management added “Bad debt expense” as an adjustment to the non-GAAP measure of Adjusted EBITDA to align with internal targets, budgets and forecasts. The prior periods have been recast to conform with the current period presentation.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with Sientra’s financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measures provided in the schedules below.

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons (*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.
(*) Data on file

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are made only as of the date of this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information concerning the Company’s unaudited financial information for the first quarter ended March 31, 2022, the impact of the COVID-19 pandemic on the Company and its operations, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, profitability, outlook and overall business strategy, the Company’s ability to successfully integrate the AuraGen fat grafting system into its existing operations, the reception of plastic surgeons to the Company’s products, the Company’s ability to expand into aesthetic applications outside of breast procedures, and the Company’s ability to capture additional market share and customer accounts in the plastic surgery market. Such statements are subject to risks and uncertainties, including the audit of the Company’s financial statements which audit is not yet complete and the numbers presented here could differ from the final audited financial statements presented by the Company, the scope and duration of the COVID-19 pandemic, the Company’s ability to recapture delayed procedures resulting from the COVID-19 pandemic, the positive reaction from plastic surgeons and their patients to the Company’s products, the ability to meet consumer demand including any potential supply issues resulting from the COVID-19 pandemic or the war in Ukraine, the growth of the plastic surgery market and breast procedures, and the ability of the Company to execute on its commercial, marketing, research and development and regulatory plans. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, and such estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.

Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com